Advances in Nano-Bio Interfaces Engineering for Electrochemical Biosensors

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Point-of-Care Diagnostics and Devices".

Deadline for manuscript submissions: closed (9 December 2022) | Viewed by 1784

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Biological Chemistry, Biophysics and Bioengineering, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh EH14 4AS, UK
Interests: biosensors; electrochemical biosensors; photoelectrochemical biosensors; nanomaterials; surface functionalisation; bioconjugation; bioelectrochemistry; cancer diagnostics; gold nanoparticles; graphene; chemiluminescence; photocatalysts

Special Issue Information

Dear Colleagues,

As the COVID-19 pandemic has reasserted the central role of effective and rapid self-monitoring at the point-of-need in the response to outbreaks, there is growing interest among the scientific community towards developing electrochemical biosensors for point-of-care diagnostic applications. Engineering nano–bio interfaces through the development of novel nanomaterials, bio functionalisation strategies, blocking chemistry, novel biomarkers, etc., plays a critical role in controlling the electron transfer pathways at the nano–bio interfaces and contributes to biosensor performance. Thus, we would like to gain new insights into the recent advances in nano–bio interface engineering for electrochemical biosensors. This Special Issue will focus on the following topics: nanomaterials, nanocomposites, biomaterials, biofunctionalisation, bioelectrochemistry, surface chemistry, blocking chemistry, anti-fouling strategies, and electrochemical biosensors.

We cordially invite those with an in-depth knowledge of the subject matter to submit a manuscript to this Special Issue of Diagnostics. Manuscripts addressing the current challenges in translating nano–bio interface engineering strategies to the large-scale manufacturing of point-of-care diagnostics will be accepted.

Dr. Anitha Devadoss
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3551 KiB  
Article
Impedimetric Detection Based on Label-Free Immunoassay Developed for Targeting Spike S1 Protein of SARS-CoV-2
by Arzum Erdem, Huseyin Senturk, Esma Yildiz and Meltem Maral
Diagnostics 2022, 12(8), 1992; https://doi.org/10.3390/diagnostics12081992 - 17 Aug 2022
Cited by 4 | Viewed by 1507
Abstract
After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was [...] Read more.
After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was developed and applied for rapid, reliable, sensitive and selective detection of the SARS-CoV-2 S1 protein. To detect the SARS-CoV-2 virus, targeting of the spike S1 protein was achieved herein by using S1 protein-specific capture antibody (Cab-S1) immobilized screen-printed electrode (SPE) in combination with the electrochemical impedance spectroscopy (EIS) technique. With the impedimetric immunosensor, the detection limit for S1 protein in buffer medium was found to be 0.23 ng/mL (equal to 23.92 amol in 8 µL sample) in the linear concentration range of S1 protein from 0.5 to 10 ng/mL. In the artificial saliva medium, it was found to be 0.09 ng/mL (equals to 9.36 amol in 8 µL sample) in the linear concentration range of S1 protein between 0.1 and 1 ng/mL. The selectivity of the impedimetric immunosensor toward S1 protein was tested against influenza hemagglutinin antigen (HA) in the buffer medium as well as in artificial saliva. Full article
Show Figures

Graphical abstract

Back to TopTop